J Breast Cancer.  2019 Jun;22(2):336-340. 10.4048/jbc.2019.22.e17.

Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy

Affiliations
  • 1Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea. sooyoun.cho@samsung.com

Abstract

Mucinous carcinoma (MC) is a rare subtype of breast cancer, which is composed of tumor cells floating in the abundant extracellular mucin. This form of cancer is usually estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) negative. Here, we present a case of HER2-positive MC with an unusual signet ring cell differentiation. It is very rare that a breast tumor consists entirely of signet ring cells. The tumor showed pathologic complete response (pCR) after neoadjuvant chemotherapy with trastuzumab and pertuzumab. pCR of HER2-positive MC has rarely been described in literature. It is important to consider the biological heterogeneity of MCs for effective management.

Keyword

Breast neoplasms; Receptor, ErbB-2; Adenocarcinoma, mucinous; Neoadjuvant therapy; Carcinoma, signet ring cell

MeSH Terms

Adenocarcinoma, Mucinous
Breast Neoplasms
Carcinoma, Signet Ring Cell
Cell Differentiation*
Drug Therapy*
Epidermal Growth Factor*
Estrogens
Humans*
Mucins
Neoadjuvant Therapy
Polymerase Chain Reaction
Population Characteristics
Receptor, Epidermal Growth Factor*
Receptor, ErbB-2
Trastuzumab
Epidermal Growth Factor
Estrogens
Mucins
Receptor, Epidermal Growth Factor
Receptor, ErbB-2
Trastuzumab
Full Text Links
  • JBC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr